Report Interpretation

Overview

This quick note assesses Hengrui's out-licensing of ex-greater China rights to HRS-1596, a GLP-1/GIP dual receptor agonist, to Novo Nordisk. Nomura views the transaction as financially supportive and as validation of Hengrui's drug-development platform, while maintaining its Buy rating and CNY61.10 target price.

Core views

On 29 September 2026, Hengrui announced that it had licensed the ex-greater China rights to HRS-1596 to Novo Nordisk. HRS-1596 is a GLP-1/GIP dual receptor agonist with potential once-weekly oral dosing. In exchange, Hengrui is to receive a USD300mn upfront payment, may receive up to USD2.3bn in development, regulatory and commercial milestones, and is entitled to sales royalties. The transaction is expected to close in 4Q26E. Nomura believes HRS-1596's potential first-in-class positioning was an important attraction for Novo Nordisk. In particular, a once-weekly oral regimen could require less frequent dosing than once-daily oral GLP-1 drugs. The institution sees the agreement as part of Novo Nordisk's effort to catch up with Eli Lilly in an early-stage area. HRS-1596 has received approval in China to begin Phase I trials in weight management and type 2 diabetes; management expects the first obesity patient to be enrolled in late 2026E and preliminary data in 2027E. This is Hengrui's second out-licensing deal year to date and its fourth GLP-1 candidate licensed out. Nomura expects the deal to be positive for the shares after recent weak performance. Hengrui had declined 19% over the preceding 60 days, compared with a 2% gain for CSI300 healthcare, amid concerns over sluggish fundamentals. Beyond the direct financial contribution, Nomura argues that the transaction could improve sentiment by underscoring Hengrui's position as a Chinese pharmaceutical R&D player with broad GLP-1 capabilities. The timing of revenue recognition matters for the financial effect. If the USD300mn upfront payment is recognized in FY27F, Nomura expects it to support its CNY3.5bn collaboration-revenue forecast. If it is recognized in 4Q26F, it would exceed the institution's existing CNY3.4bn estimate. Nomura maintains Buy and a CNY61.10 target price; the stock trades at 31.9x FY26F diluted EPS of CNY1.39.

Analysis framework

Nomura evaluates the licensing economics, HRS-1596's dosing and development profile, the competitive context for Novo Nordisk, and the potential timing of upfront-payment recognition. It then links these factors to Hengrui's collaboration-revenue estimates, market sentiment and DCF-based valuation.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow valuation

  Nomura bases its CNY61.10 target price on a DCF model using an 8.7% WACC and 5.0% terminal growth rate.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Hengrui 600276 CH / 1276 HK

  Primary subject; the HRS-1596 licensing deal is expected to support collaboration revenue and sentiment.

  Strengths

  Comprehensive GLP-1 modalities and potential once-weekly oral dosing for HRS-1596.

  Weaknesses

  Recent share performance reflected concerns about sluggish fundamentals.

  Comparison

  The shares declined 19% over 60 days versus a 2% gain for CSI300 healthcare.

  Risks

  Price cuts in the next VBP round, a narrowing valuation premium, and unsuccessful business-development or clinical progress.

Key data

• Upfront paymentUSD300mnPayment to Hengrui under the HRS-1596 licensing agreement.
• Potential milestone paymentsUp to USD2.3bnDevelopment, regulatory and commercial milestones, in addition to sales royalties.
• Expected deal closing4Q26EExpected closing timing for the transaction.
• Collaboration revenue estimateCNY3.5bn FY27F / CNY3.4bn 4Q26FNomura's estimates that could be supported or exceeded depending on upfront-payment recognition timing.
• Share-price performance-19% versus CSI300 healthcare +2%Performance over the past 60 days.
• FY26F valuation31.9x P/E on diluted EPS of CNY1.39Trading valuation cited by Nomura.
• DCF assumptions8.7% WACC; 5.0% terminal growthAssumptions supporting the CNY61.10 target price.

Impact & implications

Nomura considers the transaction a potential financial contribution to collaboration revenue and a sentiment catalyst following weak share performance. It also views the deal as external validation of Hengrui's GLP-1 development breadth, though clinical and business-development execution remains important.

Risks

• Price cuts in the next round of volume-based procurement could impede achievement of the target price.
• A narrowing valuation premium could impede achievement of the target price.
• Unsuccessful business-development and clinical progress could impede achievement of the target price.

What to watch

• Expected closing of the HRS-1596 licensing transaction in 4Q26E.
• Timing of recognition of the USD300mn upfront payment.
• First patient enrollment for obesity in late 2026E and preliminary HRS-1596 data expected in 2027E.